Accessibility Menu
Hcw Biologics logo

Hcw Biologics(NASDAQ) HCWB

Market Cap$4.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-89%
1 Month-40%
$2.28
-1.09%
-0.03Today
Hcw Biologics last closing stock price
MetricPriceDate
Last closeUSD 2.302026-08-19
Hcw Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-26.87%USD 3.152026-08-12
1 month-39.95%USD 3.832026-07-20
3 month-85.14%USD 15.482026-05-21
Year to date-60.51%USD 5.822025-12-31
1 year-89.23%USD 21.362025-08-19
3 year-99.53%USD 484.802023-08-18
5 year-99.77%USD 979.202021-08-20
Since inception-99.85%USD 1,512.002021-07-20

Hcw Biologics Financials at a Glance

Market Cap

$4.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.72M

Net Income (TTM)

-$4.92M

EPS (TTM)

-$28.42

P/E Ratio

-0.08

Dividend

$0.00

Beta (Volatility)

0.48 (Low)

Price

$2.28

Volume

48,469.473

Open

$2.26

Previous Close

$2.30

Daily Range

$2.24 - $2.38

52-Week Range

$1.50 - $44.10

Estimated Earnings Date

Nov 12, 2026

HCWB News

Foolcom-Featured.png

Hcw Biologics Revenue Plunges 98 Percent

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hcw Biologics

HCW Biologics develops injectable medicines for cancer and immune diseases. Its products aim to help patients with hard-to-treat illnesses. The company’s therapies target chronic inflammation, a cause of many age-related conditions.

Lab Bench to Bedside: What HCW Biologics Sells

  • Injectable Immunotherapies: Medicines for cancers and autoimmune diseases; 100% of 2025 revenue from clinical material supply.
  • Cell Therapy Reagents: Ingredients for manufacturing cell-based treatments, used by research labs and biotech firms.
  • Drug Discovery Platforms: Technology for designing new fusion proteins, licensed to partners for further development.
  • Out-Licensed Molecules: Drug candidates licensed to other companies for use in China and other markets.

Growth Spurts and Growing Pains

  • Launched first-in-human trial for HCW9302 in November 2025.
  • Signed licensing and co-development deal with Trimmune closed in March 2026.
  • Supplied clinical materials to Wugen until 2025; revenue dropped after Wugen shifted focus.
  • Expanded headquarters and manufacturing facility in Miramar, Florida, with construction ongoing.
  • Entered equity and financing agreements in 2025 and 2026 to raise capital.

Why HCW Biologics Is a Bit Different

The company uses proprietary technology to create fusion proteins that combine multiple therapeutic effects in one drug. Its focus on chronic inflammation and cell therapy reagents addresses diseases with few treatment options. Strategic licensing and manufacturing partnerships help fund research and development.

Five Things You Need to Know

  • Revenue was $15,606 in Q3 2025, down 96.3% from Q3 2024.
  • Net loss was $7.96 million in 2025, improved from $30 million in 2024.
  • Cash and equivalents were $2.0 million at December 31, 2025.
  • All 2025 revenue came from one customer, Wugen.
  • Ongoing legal disputes and facility construction delays impact operations.

Bottom Line

HCW Biologics has shifted from early revenue to a focus on clinical trials and partnerships. The company faces financial and operational challenges as it develops new therapies for difficult diseases.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

35

CEO

Hing C. Wong, PhD

Website

www.hcwbiologics.com

Headquarters

Miramar, FL 33025, US

HCWB Financials

Key Financial Metrics (TTM)

Gross Margin

95.91%

Operating Margin

-91.57%

Net Income Margin

-73.22%

Return on Equity

-142.16%

Return on Capital

-117.58%

Return on Assets

-18.39%

Earnings Yield

-12.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.84M

Volume

48.47K

Avg. Volume

784.13K

Financials (TTM)

Gross Profit

$6.45M

Operating Income

-$6.15M

EBITDA

-$4.27M

Operating Cash Flow

-$12.14M

Capital Expenditure

-$2.00

Free Cash Flow

-$12.14M

Cash & ST Invst.

$741.32K

Total Debt

$6.56M

Hcw Biologics Performance Analysis

Hcw Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 6,722,090N/A
20232023-12-31USD 2,841,794-57.7%
20242024-12-31USD 2,566,792-9.7%
20252025-12-31USD 54,232-97.9%
Hcw Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30138.3%
Q42025-12-3173.1%
Q12026-03-3124124.4%
Q22026-06-30-97.9%
Hcw Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -99.8315.7%
20232023-12-31USD -166.9667.2%
20242024-12-31USD -185.7511.3%
20252025-12-31USD -63.78-65.7%
Hcw Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3070.3%
Q42025-12-3118.3%
Q12026-03-31219.4%
Q22026-06-30-204.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$135.57K

+1969.7%

Gross Profit

-$93.89K

-7266.9%

Gross Margin

-69.25%

N/A

Market Cap

$4.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$120.67K

N/A

Employees

35

N/A

Net Income

-$5.22M

-170.7%

EBITDA

-$4.97M

-281.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$741.32K

-69.6%

Total Debt

$6.56M

-3.3%

Accounts Receivable

$18.45K

-14.6%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$6.56M

+2.2%

Return on Assets

-18.39%

N/A

Return on Invested Capital

-75.79%

N/A

Free Cash Flow

-$3.97M

-20.8%

Operating Cash Flow

-$3.97M

-20.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RNAZTransCode Therapeutics, Inc.
$3.13-2.49%
ADILAdial Pharmaceuticals, Inc.
$5.63-2.26%
CELZCreative Medical Technology Holdings, Inc.
$1.18+4.91%
ACXPAcurx Pharmaceuticals, Inc.
$1.44+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.77+0.06%
IBITiShares Bitcoin Trust
$40.92+0.06%
SPCXSpace Exploration Technologies
$130.55-0.07%
MRNAModerna
$139.48-0.20%

Questions About HCWB

What is the current price of Hcw Biologics?

Hcw Biologics is trading at $2.28 per share.

What is the 52-week range for Hcw Biologics?

Over the past 52 weeks, Hcw Biologics has traded between $1.50 and $44.10.

How much debt does Hcw Biologics have?

As of the most recent reporting period, Hcw Biologics reported total debt of $6.56M.

How much cash does Hcw Biologics have on hand?

Hcw Biologics reported $741.32K in cash and cash equivalents in its most recent financial results.

What is Hcw Biologics’s dividend yield?

Hcw Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services